The multi-center precision medicine trial has matched approximately 700 patients to 24 treatment arms so far, but some arms appear to be falling short of their recruitment goal.
Genelex is hoping that a recently published randomized-controlled trial will help it get on better footing with Medicare.
Geneticure has raised around $1.1 million to fund the study, which may very well be the largest prospective RCT for personalization of high blood pressure treatment.
The activity follows a recent financing round that has enabled OncoDNA to build out its sales team as it courts new clients.
Strata will refer castration-resistant prostate cancer patients with BRCA and ATM mutations for potential enrollment in Clovis' Rubraca studies.
Under the deal, Novartis will access patients who have used Perthera's Precision Cancer Analysis service, which facilitates molecular profiling of cancers.
Caris will be on the lookout for pancreatic cancer patients with low DNA mismatch repair protein expression.
Researchers try to increase numbers of minorities in cancer immunotherapy trials, the New York Times reports.
Natera will design a personalized liquid biopsy assay for each patient and will test its ability to monitor disease progression and treatment response.
Progression-free and overall survival seen in the veliparib arm weren't statistically significant, but were encouraging enough to move the drug to Phase III, AbbVie said.
New research shows that scientists need to do a better job of including a wider diversity of African genomes in their analyses, STAT says.
A new paper in Science shows that men are still winning a large majority of the most sought-after NIH grants.
Nature Research and the Estée Lauder Companies are awarding efforts to encourage girls to pursue careers in the STEM fields.
In Science this week: beneficial genetic variants inherited from archaic Neanderthal and Denisovan hominins, and more.